Table 2B.
Primary endpoints (change) by study arm—adjusted analysis.
| Visits | |||||||
|---|---|---|---|---|---|---|---|
| Adjusted& mean changes from T0 | Adjusted& difference in mean changes from T0 | ||||||
| Markers | |||||||
| T0 95% CI |
T6 95% CI |
T12 95% CI |
T0 95% CI p-Value |
T6 95% CI p-Value |
T12 95% CI p-Value |
p-Value* | |
| CD4 count, cells/mm3 | |||||||
| RCT arm | 0.348 | ||||||
| DTG/3TC | −8 (−64, 49) | 12 (−45, 68) | −53 (−110, 4) | 0 | 0 | 0 | |
| B/F/TAF | 8 (−50, 67) | −30 (−89, 29) | −29 (−87, 30) | −41 (−125, 42) | 24 (−59, 108) | ||
| 0.330 | 0.564 | ||||||
| CD8 count, cells/mm3 | |||||||
| RCT arm | 0.457 | ||||||
| DTG/3TC | −12 (−79, 56) | 13 (−55, 80) | −62 (−129, 6) | 0 | 0 | 0 | |
| B/F/TAF | 13 (−57, 82) | −27 (−97, 42) | −46 (−115, 24) | −40 (−139, 59) | 16 (−83, 115) | ||
| 0.428 | 0.751 | ||||||
| CD4/CD8 ratio, units | |||||||
| RCT arm | 0.626 | ||||||
| DTG/3TC | 0.0 (−0.1, 0.1) | 0.0 (−0.0, 0.1) | 0.0 (−0.0, 0.1) | 0 | 0 | 0 | |
| B/F/TAF | −0.0 (−0.1, 0.1) | 0.0 (−0.1, 0.1) | 0.1 (−0.0, 0.1) | −0.0 (−0.1, 0.1) | 0.0 (−0.1, 0.1) | ||
| 0.717 | 0.531 | ||||||
RCT, randomized clinical trial; VL, viral load.
* F-test type 3 interaction p-value.
& Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD4 count nadir.